Each year, approximately 20 million people are diagnosed with cancer, and nearly 10 million lives are lost to the disease ...

The lymphopenia opportunity was until recently under-emphasized by ImmunityBio. For example, in their general corporate presentation from January of this year, the word "lymphopenia" was not ...

ImmunityBio Inc. (NASDAQ:IBRX) is one of the 13 Stocks Under $5 With High Upside Potential. ImmunityBio Inc. (NASDAQ:IBRX) ...

NetworkNewsWire Editorial Coverage NEW YORK, July 9, 2025 /PRNewswire/ -- Each year, approximately 20 million people are diagnosed with cancer, and nearly 10 million lives are lost to the ...

To date no treatment exists for lymphopenia, a depletion of critical lymphocytes responsible for immunogenic cell death, specifically natural killer (NK) cells, killer CD8+ T cells and CD4+ with ...

Welcome to Fierce Pharma's regulatory tracker for the second half of 2025. | In this tracker, Fierce Pharma is recording the ...

ImmunityBio Inc. scored a win earlier this month. The Culver City-based company announced that the U.S. Food and Drug Administration has granted “expanded ...

ImmunityBio Inc. (NASDAQ:IBRX) is one of the 13 Best Long-Term Penny Stocks to Buy According to Analysts. On June 2, ImmunityBio Inc. (NASDAQ:IBRX) announced that it attained Expanded Access ...

ImmunityBio, Inc. (NASDAQ: IBRX) today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has ...

Chikungunya which is reported from many parts of the country during the past few weeks is a viral disease transmitted to ...

ImmunityBio, Inc. (NASDAQ:IBRX) ranks among the 30 stocks expected to beat the market by 20 percentage points this year. With ...